S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH (2014/12/8)|
|ADDING MULTIMEDIA FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma (2015/2/19)|
|FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma (2015/2/18)|
|Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant (2014/12/19)|
|Aegerion Pharmaceuticals Reports Preliminary 2014 Net Product Sales, Its Outlook for 2015 and Other Business Updates (2015/1/12)|
|Aegerion Pharmaceuticals Completes Acquisition of MYALEPT(R) (2015/1/12)|
|Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis (2014/12/10)|
|Five-Year Data From SABRIL® (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting (2014/12/8)|
|Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome (2015/1/12)|
|Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone) (2015/1/23)|
Click above to view more mutual fund data and stats for rem - Remgro Ltd.